A collaborative effort between physicians and pharmacists appears to result in improved blood pressure control in hypertensive patients, and continued education in smoking cessation counseling may help physicians, according to two articles published Oct. 11, 2010 in the Archives of Internal Medicine, HealthDay News reported.
A collaborative effort between physicians and pharmacists appears to result in improved blood pressure (BP) control in hypertensive patients, and continued education in smoking cessation counseling may help physicians, according to two articles published Oct. 11, 2010 in the Archives of Internal Medicine, HealthDay News reported.
Cynthia A. Weber, PharmD, of the University of Iowa, and colleagues randomized 179 patients with uncontrolled hypertension to receive pharmacist-physician collaborative management or usual care over 9 months. Researchers found 75% of the patients in the collaboration group achieved BP control, compared with 50.7% in the usual care group.
One author disclosed a financial arrangement with Takeda Pharmaceuticals.
In a separate study, Alexander V. Prokhorov, MD, PhD, of the University of Texas’ M.D. Anderson Cancer Center, and colleagues examined surveys from 87 physicians and 83 pharmacists to evaluate the effectiveness of continuing education training on cessation counseling. Researchers found a significant increase in the percentage of physicians and pharmacists in the intervention group (smoking cessation training), with greater perceived ability, confidence, and intention to address smoking issues post-training versus members of the control group (who underwent skin-cancer prevention training). Researchers concluded that training improved counseling among physicians.
Navitus to Offer Unbranded Stelara Biosimilar, Remove Stelara from Formulary
March 13th 2025Lumicera Health Services, Navitus’ specialty pharmacy, has made a deal with Teva to offer an unbranded biosimilar that they estimate will save $112,000 and $336,000 per patient per year. Navitus will remove Stelara from formulary on July 1, 2025.
Read More
FDA Approves Neffy 1 mg Nasal Spray for Pediatric Patients
March 6th 2025Neffy 1 mg is now approved by the FDA to treat pediatric patients who weigh 33 to 65 lbs. Neffy was first FDA-approved as a 2 mg dose in August 2024 for the emergency treatment of anaphylaxis in children and adults weighing at least 66 lbs.
Read More